Our Global Policy Position on Partnering with Patient Organizations

BeiGene’s Position

At BeiGene, our core value is putting patients first. We seek to improve the health and well-being of patients globally by developing and improving access to impactful medicines, and by focusing on the whole patient. We believe collaboration with patient organizations is key to achieving these shared goals. We aspire to be a trusted and thoughtful partner to them and the patient communities they serve. Our ambition is to continue to expand our partnerships with patient organizations, to drive patient-centric change in health policy to improve the global cancer care ecosystem.

Why BeiGene partners with patient organizations

Patient organizations are increasingly active in shaping the healthcare environment and play an important role in improving patient care. By interacting directly with patients, these groups are uniquely positioned to provide valuable, real-time insights into the patient and caregiver experience and how the healthcare environment can be improved to address their needs.

We recognize that partnering with patient organizations is important to:

- Understand patient and caregiver needs and thread this throughout the fabric of the company
- Integrate diverse patient perspectives early and often into clinical development programs
- Advance oncology, health equity, and public health policy to reduce disparities and improve access to and delivery of medicines
- Co-develop collaborative partnerships with multilateral organizations and change the healthcare ecosystem for the better
- Engage, educate, and mobilize BeiGene colleagues to demonstrate commitment to the whole patient throughout their cancer journey
- Approach our work and interactions in a meaningful, culturally specific, appropriate, and relevant manner

Patient organizations that BeiGene partners with

As a cancer-focused company, we are passionate about working with patient organizations that share our ambition of improving the lives of cancer patients and their caregivers. We partner with organizations around the world that are active in the disease states of interest addressed by our medicines and those that support the patient and family experience.

In the US, we have a specific interest in improving mental health for people impacted by cancer and believe that this is a critical component of the cancer experience. We aim to partner with like-minded advocacy organizations to highlight the importance of mental health and improve health outcomes for people with cancer and those that care for them.
Types of partnerships

We partner with and support patient organizations on a broad range of activities including convening forums, conducting research, developing and disseminating educational materials and undertaking awareness campaigns. Examples of our engagement include:

- **Forums** – We conduct international, regional, and country forums, to introduce BeiGene to the patient community, facilitate information exchange and identify ways we can better support patients. In 2021, we hosted our first Global Advocacy Forum comprised of representatives from 20 patient organizations from around the world.

- **Educational materials** – We work with patient organizations to create educational materials for patients, caregivers, and healthcare professionals to improve disease knowledge and shared decision-making. In China and Europe, we partnered with patient communities and non-profit organizations to develop educational resources for people living with cancer.

- **Awareness campaigns** – We collaborate with patient groups to increase general public awareness of cancer and to improve earlier detection. In Italy, we have worked alongside Women Against Lung Cancer in Europe to develop a social media campaign on lung cancer to help the public more easily recognize the symptoms and reduce the stigma around the disease.

- **Public Policy** – We partner with advocacy organizations to align on and advance public policy that supports the needs of the cancer community. In the U.S., we have worked alongside our advocacy partners to support federal legislation around clinical trial diversity and continue to engage in regulatory conversations on the accelerated approval process. In Europe, we have supported the International COVID-19 Blood Cancer Coalition, a multi-stakeholder coalition committed to addressing the specific impact of the pandemic on immunocompromised blood cancer patients.

- **Mental Health** – We elevate important conversations to support integrating mental health care into comprehensive cancer care to improve patient outcomes and support caregiver needs. In 2022, we partnered with the Cancer Support Community to conduct a study on barriers to mental health care and patient needs in order to inform the design and launch of BeiGene’s new signature program on cancer and mental health, Talk About It.

Interacting with patient organizations

When interacting with patient organizations, we commit to the highest standards of integrity and adherence to industry codes and relevant laws relating to patient engagement and advocacy. This commitment includes honoring the independence of patient organizations in their political judgement, strategies, policies, and activities; ensuring that the objectives and scope of our partnerships are transparent and guided by patient organizations; and that all financial or non-financial support is clearly acknowledged.iii

At BeiGene, patient advocacy relationships are generally managed by the patient advocacy team. To contact the team and learn more, please email us at patientadvocacy@beigene.com.

---

i BeiGene ESG Report 2021
ii BeiGene Code of Conduct